⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SABS News
SAB Biotherapeutics, Inc. Common Stock
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
globenewswire.com
SABS
EBS
Form 8-K
sec.gov
SABS
SABSW
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
globenewswire.com
SABS
SABSW
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
globenewswire.com
SABS
SABSW
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
SABS
Form 8-K
sec.gov
SABS
SABSW
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
SABS
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
SABS
SABSW
Form 8-K
sec.gov
SABSW
SABS
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
globenewswire.com
SABS
SABSW